# New from Roche

# BACTRIM double strength

## CONVENIENT/ECONOMICAL/EFFECTIVE

The well-proven combination of trimethoprim and sulphamethoxazole (co-trimoxazole) now available in a convenient **one-tablet b.i.d.** form.

*Indications*
Treatment of infections of the respiratory tract, urinary tract, gastro-intestinal tract, skin and soft-tissue.

*Dosage*
Standard adult dosage: 1 Double Strength tablet twice daily.
Minimum dosage (for long-term therapy): ½ Double Strength tablet twice daily.
Maximum dosage: 1½ Double Strength tablets twice daily.

*Contra-indications*
Marked liver parenchymal damage or blood dyscrasias, severe renal insufficiency, sulphonamide hypersensitivity, pregnancy, premature and newborn babies.

*Precautions*
Maintain an adequate urinary output. Reduce dosage in renal impairment. Regular blood counts are advisable with long-term therapy. Special caution is required in patients predisposed to folate deficiency.

The usual caution in prescribing any drug for women of childbearing age should be exercised. Both trimethoprim and sulphamethoxazole are excreted in breast milk.

*Side-effects*
Nausea, vomiting, glossitis, skin rashes and blood dyscrasias can occur. Discontinue treatment if a skin rash appears. Elderly patients are more prone to blood dyscrasias. Megaloblastic changes in the bone marrow are reversible with folinic acid.

*Presentation*
Bactrim Roche Double Strength tablets, each containing 160mg trimethoprim and 800mg sulphamethoxazole, in packings of 50.

Product licence number: PL 0031/0110

Bactrim Roche is also available as single-strength tablets (dispersible), Drapsules, paediatric tablets, adult suspension and paediatric syrup.

ROCHE

Full prescribing information is available.
Roche Products Limited, PO Box 2LE, 15 Manchester Square, London W1A 2LE



J098218/1177

## DOCTORS ABROAD

Copies of vacancies advertised in the *Journal* can be sent AIRMAIL. For members of the BMA there is no charge for five weeks' supply covering five separate headings. Non-members' rate: £6 minimum for six weeks' supply of five headings or less. Additional headings for non-members: 50p each for six weeks' supply. Orders for specific grades cannot be accepted.

Payment by non-members must be PREPAID and enclosed with application.

# Prothiaden

## What's the significance of the new 75mg tablet?

*Presentation* Prothiaden is dothiepin hydrochloride, an antidepressant of the tricyclic group.
Prothiaden is available as sugar-coated tablets, each containing 75mg of dothiepin hydrochloride. The tablets are red in colour and bear the overprint 'P 75' in white. It is also available in hard gelatin capsules, each containing 25mg of dothiepin hydrochloride. The capsules are red-brown in colour with the overprint 'P25' in white.

*Uses* Prothiaden is indicated in the treatment of depression and the anxiety frequently associated with depressive illness.

*Dosage and Administration* Prothiaden should be given in a dosage of 75 to 150mg daily. The following dosage schemes are suggested:
Mild to moderate depression, 25mg three times daily or 75mg at night.
Moderate to severe depression, 150mg daily in divided doses, or as a single dose at night. (If the latter regimen is adopted, it is preferable to use a smaller dose for the first few days).
In certain circumstances, i.e. in hospital use, Prothiaden has been given at dosages up to 225mg daily. No dietary restrictions are necessary during treatment with Prothiaden.

*Contra-indications, Warnings, etc.* Prothiaden has anticholinergic properties; therefore, it may precipitate urinary retention in susceptible individuals and its use should be avoided in patients with existing or potential urinary retention. Patients with closed-angle glaucoma should not be given Prothiaden and the occurrence of a painful red eye in a patient receiving the drug may indicate acute closed-angle glaucoma; this requires urgent treatment. In patients with chronic simple glaucoma, the risk of Prothiaden causing a rise in intraocular pressure is relatively small provided adequate anti-glaucoma therapy is being used. Caution is advised when treating epileptic patients and those with cardiovascular disorders. From studies in animals, it was concluded that Prothiaden had no teratogenic effects in the species tested. Nevertheless, as with any relatively new drug, the use of Prothiaden during pregnancy should be avoided if possible.

*Use with other drugs:* Prothiaden should not be given concurrently with MAO inhibitors; nor should it be given within 14 days of ceasing treatment with an MAO inhibitor. Prothiaden may alter the pharmacological effects of some concurrently administered drugs: CNS depressants, including alcohol and narcotic analgesics, will be potentiated, as will the effects of adrenaline and noradrenaline (it should be borne in mind that some local anaesthetic preparations contain these sympathomimetics). The hypotensive effect of certain antihypertensive agents (e.g. bethanidine, debrisoquine, guanethidine) may be reduced.

*Side-effects:* Generally, the side-effects associated with Prothiaden have been mild and controlled by reduced dosage. The following have been reported – dryness of mouth, constipation, disturbed accommodation, lassitude, dizziness, orthostatic hypotension, palpitations, somnolence, tremor, headache.

*Overdosage:* The symptoms of overdosage with Prothiaden may include sedation, dry mouth, blurring of vision, tachycardia, tremor, sweating, nausea, vomiting, confusion. The main dangers from overdosage arise from unconsciousness, convulsions, abnormal cardiac rhythms, hypotension and depression of respiration. The smallest dose of Prothiaden alone which resulted in the death of an adult was reported to be 0.75–1.0g (30 to 40 x 25mg capsules). The largest dose from which recovery took place was reported to be 5.0g (200 x 25mg capsules). In view of the many factors which influence the outcome of an overdose, these figures should not be considered in isolation.

Treatment of overdosage: Gastric lavage: in the unconscious patient or where the cough reflex is depressed, the lungs should be protected by a cuffed endotracheal tube. Repeated gastric/intestinal aspiration may remove drug and metabolites excreted into the gut via the bile. General support of the circulation with continuous ECG monitoring is advised. Abnormalities of cardiac rhythm and epileptic convulsions may occur and should be treated accordingly. Forced diuresis and haemodialysis are not recommended. Bed-rest is advisable, even after clinical recovery.

*Pharmaceutical Precautions* – Recommended storage conditions 5°C to 20°C.

*Legal Category* POM.

*Package Quantities* – Prothiaden Tablets (75mg) 100, 500. Prothiaden Capsules (25mg) 100, 600.
*Basic NHS Prices:* 100 x 25mg £1.57 600 x 25mg £9.03
100 x 75mg £4.52 500 x 75mg £21.70
*Product Licence Number* Prothiaden capsules PL 0096/5007. Prothiaden Tablets PL 0096/0046.

The Crookes Laboratories Ltd., Basingstoke, Hants.

**References:** 1. Pearce, J. B. & Linford Rees, W. J., Int. Med. Res. 1974, **2**, 12.
2. Rees, J. A. & Cryer, P. C. Curr. Med. Res. Opin. 1976, **4**, 416.

...dothiepin in a single daily dose is better tolerated and produces a greater overall response than a divided dose regimen of amitriptyline. 2

...A single daily dose of dothiepin (Prothiaden) has been shown to produce a better clinical response and to be better tolerated than a divided daily dose regimen. 1

...'with dothiepin both the incidence and severity of side-effects were much less than with amitriptyline.' 2

# Prothiaden 75mg

## more effective, better tolerated treatment for depression and anxiety.

# NOTICE TO ADVERTISERS

## Display Advertisements

Applications for advertisement space and for rates should be addressed to the Advertisement Manager, *British Medical Journal*, B.M.A. House, Tavistock Square, London WC1H 9JR. 01-387 4499. Telegrams: Aitiology, London WC1. Telex 265929.

## Classified Advertisements

Please write advertisements and name and address clearly in BLOCK CAPITALS and send to the Advertisement Manager, *British Medical Journal*, B.M.A. House, Tavistock Square, London WC1H 9JR. For immediate insertion please enclose cheque in payment and state whether member or non-member. Classified rates for Doctors' advertisements are as follows:

**MEMBERS RATE:** Minimum charge £2.00 for eighteen words, additional words at the rate of 50p for each six or less. Name and address count word for word. **A Box Number counts as three words, and an additional charge of 40p is made for sorting and forwarding Box Number replies.**

**NON-MEMBERS RATE:** Minimum charge £3.30 for eighteen words, additional words at the rate of £1.10 for each six or less. Name and address count word for word. **A Box Number counts as three words, and an additional charge of 40p is made for sorting and forwarding Box Number replies.**

**APPOINTMENTS: EDUCATIONAL: NOTICES AND HOMES:** Minimum charge £2.88 for four lines and 72p for each additional line. **Box Number address counts as one line, and 40p to be added for postage of replies.**

**GENERAL AND COMMERCIAL (TRADE):** Personal: Accommodation: Nursing: Consulting Rooms: Houses and Property: Travel: Hotels: Nursing: Medical and Secretarial Agencies: Commercial. Minimum charge £3.60 for 18 words including name and address and telephone number. Each additional six words or less £1.20. **Box No's count as three words. Advertisers using a box number should add 40p for postage replies.**

## Semi-Display Advertisements

£5.50 per single column cm and pro rata. Full page £550. Half page £275. **Mechanical Data:** Classified: col. length 25.7cm, single col. width 4.4cm, double col. width 9.3cm, 3 col. width 14.2cm, full page width 19.1cm. Minimum depth of semi-display advertisements is three single column centimetres. Complete artwork required for s.c. semi-display advertisements. Printed offset litho.

**All classified advertisements, subject to approval, will appear in the forthcoming issue provided they reach this office not later than 10a.m. on the Friday of the week preceding date of issue. Semi-display advertisements must reach this office by 10a.m. on the Tuesday of the week preceding date of issue.**

**Cancellation and corrections of advertisements must be received before 12 noon on the Friday of the week preceding date of issue (issues affected by public holidays excepted).**

*It is requested that when stamped addressed envelopes are enclosed in response to advertisements advertisers will ensure that a reply is sent.*

*Every effort is made to ensure the accuracy of advertisements appearing in the Journal. No recommendation is implied by acceptance, and the Editor of the British Medical Journal reserves the right to refuse, discontinue or interrupt the insertion of any advertisement.*

# NOTICE TO READERS

**REPLIES TO BOX NUMBERS.** The names and addresses of advertisers under box numbers are held by us in strict confidence and cannot be disclosed. Each Box Number should be addressed separately. Two or more replies can be enclosed in one envelope. The replies will be forwarded to the advertisers in plain envelopes.

# NOTICE TO SUBSCRIBERS

**United Kingdom and Irish Republic Edition.** The annual subscription rates for members of the medical profession who are not members of the B.M.A. is £40.00. Subscriptions can be ordered direct from the Subscription Manager, *British Medical Journal*, B.M.A. House, Tavistock Square, London WC1H 9JR, or through any leading subscription agent or bookseller.

**Overseas Edition (not containing classified advertisements).** The rate for non-members is US$56.00 or the equivalent in local currencies, direct from the Subscription Manager. Orders can also be placed through any leading subscription agent or bookseller. Readers in the U.S.A. can send their subscription order with or without payment to: *British Medical Journal*, 1172 Commonwealth Avenue, Boston, Mass. 02134.

**Single Copies** of issues published in the current year cost 80p in the United Kingdom and Irish Republic and US$2.00 overseas. Back number prices on application to the Subscription Manager.




# Introducing our second generation generator

**The Radiochemical Centre Amersham**

The Radiochemical Centre Limited, Amersham, England. Tel: Little Chalfont (024 04) 4444
In West Germany: Amersham Buchler GmbH & Co KG, Braunschweig. Tel: 05307-4693-97